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Unlike other types of T helper (Th) responses,
whether the development of Th2 cells requires in-
struction from particular subset of dendritic cells
(DCs) remains unclear. By using an in vivo depletion
approach, we have shown that DCs expressing
CD301b were required for the generation of Th2 cells
after subcutaneous immunization with ovalbumin
(OVA) along with papain or alum. CD301b+ DCs are
distinct from epidermal or CD207+ dermal DCs
(DDCs) and were responsible for transporting anti-
gen injected subcutaneously with Th2-type adju-
vants. Transient depletion of CD301b+ DCs resulted
in less effective accumulation and decreased
expression of CD69 by polyclonal CD4+ T cells in
the lymph node. Moreover, despite intact cell
division and interferon-g production, CD301b+ DC
depletion led to blunted interleukin-4 production by
OVA-specific OT-II transgenic CD4+ T cells and
significantly impaired Th2 cell development upon
infection with Nippostrongylus brasiliensis. These
results reveal CD301b+ DDCs as the key mediators
of Th2 immunity.
INTRODUCTION
Proper differentiation of T helper (Th) cells into distinct effector
subsets—Th1, Th2, Th17, or regulatory T cells—dictates protec-
tive immunity against distinct classes of pathogens (Sacks and
Noben-Trauth, 2002; Zhu et al., 2010). It is generally believed
that the fate of effector Th differentiation is determined by the na-
ture of antigen-presenting cells (APCs) that prime naive CD4+
T cells (Moser and Murphy, 2000). In the case of differentiation
into Th1, Th17, or regulatory T cells, migratory dendritic cells
(DCs) that capture antigens in the peripheral organ and carry
them to the draining lymph nodes (dLNs) play a direct role in
Th cell differentiation (Brewig et al., 2009; Guilliams et al.,
2010; Igya´rto´ et al., 2011; King et al., 2010). Previous studies
have shown that a subset of DCs distinct from those that induce
Th1 cell differentiation, namely CD8a DCs, preferentially
generate Th2 cell responses both in vivo and in vitro, suggesting
the presence of subset-specific Th2 cell-driving cue (Maldo-nado-Lo´pez et al., 1999; Pulendran et al., 1999; Tang et al.,
2010). However, despite previous demonstration that innate
cell types including DCs and basophils play an indispensable
role in eliciting Th2 cell-mediated immune responses (Hammad
et al., 2010; Leo´n et al., 2012; Ohnmacht et al., 2010; Otsuka
et al., 2013; Perrigoue et al., 2009; Phythian-Adams et al.,
2010; Smith et al., 2012; Sokol et al., 2009; Tang et al., 2010;
Yoo et al., 2010; Yoshimoto et al., 2009), whether the differenti-
ation of naive CD4+ T cells into Th2 cells in vivo requires a
specialized population of APCs in the priming phase remains un-
clear (Kool et al., 2012; Pulendran and Artis, 2012).
Cysteine proteases, such as papain and house dust-mite an-
tigen DerP1, exemplify a class of noxious substance that reflects
activity of helminthes and allergens (Palm et al., 2012). Skin rep-
resents an essential protective barrier against infectious agents
including helminthes. It is well documented that subcutaneous
injection of certain cysteine protease alone can trigger robust
Th2 cell responses in vivo (Kikuchi et al., 2006; Sokol et al.,
2008; Tang et al., 2010), though the type of APCs or pattern-
recognition receptors that directly recognizes those proteases
or their activity to induce Th2 immunity is unknown. In the skin,
there are three distinct subsets of DCs that serve as APCs that
potentially migrate to the dLN to activate naive lymphocytes
(Merad et al., 2008). Epidermal Langerhans cells (LCs) and
CD103+ dermal DCs (DDCs) are the two subsets of DCs that ex-
press CD207 (Langerin) and are important for differentiation of
Th17 and Th1 cells, respectively (Kaplan et al., 2012). It has
been previously reported that skin-resident CD207+ DCs,
including LCs and CD103+ DDCs, do not efficiently transport
protein antigens coinjectedwith papain to the dLN and are there-
fore not responsible for the papain-induced Th2 cell responses
(Tang et al., 2010). Although these findings leave open the
possibility that other subset of skin-migratory DCs, namely
CD207 DDCs, in mediating Th2 cell differentiation, in vivo role
of this dominant DC subset in the dermis is largely unknown.
On the basis of the selective expression of a CD301b, also
known as macrophage galactose-type C-type lectin 2 (Mgl2),
in CD207 DDCs (Kumamoto et al., 2009), we generated mice
in which the DDC population could be specifically and inducibly
depleted. Here, we have examined the requirement for CD301b+
DDCs in the generation of Th2 cell-mediated immunity following
immunization with antigen plus papain. We have extended
our analysis to another widely used Th2-type adjuvant, alum,
as well as to a natural rodent pathogen, Nippostrongylus
brasiliensis, that induces robust Th2 cell responses. Our results
reveal a requirement for CD301b+ DDCs in the generation ofImmunity 39, 733–743, October 17, 2013 ª2013 Elsevier Inc. 733
Figure 1. Expression of CD301b by the Ma-
jor DCPopulation in the Dermis and Submu-
cosae
(A) Expression of CD301b, CD326 (LC marker),
and CD103 (CD207+DDC marker) in naive cuta-
neous LN. Cells within the CD11c+MHCII+B220
gate are shown.
(B) Frozen sections of skin, vagina, esophagus,
and tongue from naive C57BL/6micewere stained
with Ab against CD301b (green), CD207 (red, left),
and CD11c (red, right). Scale bar represents
100 mm. E, epidermis; L, lumen. These data are
representative of three or more similar experi-
ments. See also Figure S1.
Immunity
CD301b+ Dermal DCs Drive Th2 Cell ResponsesTh2 cell-mediated immunity and describe the key defects in
CD4+ T cell priming in the absence of these DDCs.
RESULTS
CD301b Is Expressed by Dermal and Submucosal DC
Subsets that Are Distinct from CD207+ DCs
To address the function of DDCs in vivo, we utilized CD301b, a
specific marker of CD207 DDCs in the skin (Kumamoto et al.,
2009). We developed a monoclonal antibody (mAb) against
CD301b that is not cross-reactive to a closely related homolog,
CD301a (see Figure S1 available online). CD301a is expressed
more broadly by DCs and plasmacytoid DCs, whereas
CD301b is expressed by DDCs in the dermis and subcutaneous
LNs but not in the spleen (Kumamoto et al., 2009). Staining naive
skin-draining LN (dLN) cells with the anti-CD301b mAb
confirmed that CD301b+ DDCs expressed neither CD103 nor
CD326, markers for CD207+ DDCs and LCs, respectively (Nagao
et al., 2009) (Figure 1A). Moreover, CD301b+ CD11c+ cells were
present only in the dermis and submucosa underneath squa-
mous stratified epithelia and were excluded from the epithelial
layer inhabited by the LCs (Figure 1B). These results indicate
that expression of CD301b marks a unique subset of DCs within
the subepithelial regions in multiple mucosal organs and skin.
CD301b+ DDCs Efficiently Transport Protein Antigen
Injected in the Footpad
To test the ability of DC subsets to take up antigens in vivo,
we immunized mice in the footpad with fluorescently-labeled
ovalbumin (OVA) together with the Th2-type adjuvant papain
or the Th1-type adjuvant CpG and analyzed cells that had taken
up OVA in the dLN 24 hr after injection. Although CD301b+ DDCs
were capable of taking up OVA regardless of the adjuvant used,
papain induced selective uptake of OVA by CD301b+ DDCs (Fig-
ure 2; Figure S2). In addition, the percentage of CD301b+ DC in
the dLNs increased dramatically in papain-injected mice
compared to PBS-injected mice or naive control, suggesting
that OVA uptake occurred in CD301b+ DDCs that had migrated734 Immunity 39, 733–743, October 17, 2013 ª2013 Elsevier Inc.from the dermis to the dLN. Together with
a previous report showing that CD301b+
DDCs are the earliest migrants following
hapten painting on the skin (Kumamoto
et al., 2009), our data demonstrate theCD301b+DDCs as a key transporter for cutaneous antigens to
the dLN in vivo.
CD301b+DDCs Are Depleted upon Injection of
Diphtheria Toxin in Mgl2DTR Mice
To selectively and transiently deplete CD301b+ DDC in vivo, we
generated mice in which a diphtheria toxin receptor (DTR)-GFP
cassette was genetically targeted into the first coding exon of
CD301b, or the Mgl2 gene (Figure S3A). Both homozygous and
heterozygous mice were healthy and born at the expected Men-
delian ratio. The GFP fluorescence in the homozygotes
confirmed selective expression of the DTR-GFP fusion protein
in CD301b+ DDCs (Figures S3B and S3C). From hereafter we
use only Mgl2+/DTR-GFP heterozygotes for experiments and refer
to them as Mgl2DTR mice. In Mgl2DTR mice, a single intraperi-
toneal injection of DT selectively depleted CD301b+ DDCs in
the skin-draining LNs (Figures 3A and 3B). The depletion lasted
for at least 6 days after a single DT injection (Figure 3C). When
mice were painted with a fluorescent dye TRITC on the skin,
the dLNs of the CD301b+ DDC-depleted mice were almost
completely devoid of TRITC-bearing cells at 24 hr after the paint-
ing (Figure 3D). These data indicate that, unlike the CD207+ DCs
(Kissenpfennig et al., 2005), CD301b+ DDCs account for the ma-
jority of themigratory skin-derived DCs early after sensitization in
the skin.
Experiments with congenic bone-marrow chimeric mice indi-
cated that CD301b+ DDCs are derived from circulating radio-
sensitive precursors (Figures S4A and S4B), consistent with
the published reports (Bogunovic et al., 2006; Ginhoux et al.,
2007). Unexpectedly, however, despite undetectable expression
of either DTR-GFP or endogenous CD301b protein by LCs, DT
injection also reduced LC frequency within the epidermis (Fig-
ure S4C), but not in the skin-dLNs (Figure 3B; Figure S4D).
Depletion of epidermal LCs was not observed in bone-marrow
chimeric mice in which Mgl2DTR bone-marrow cells were trans-
planted into lethally irradiated wild-type (WT) mice (Mgl2DTR/
WT chimera), whereas conversely, DT treatment of WT/
Mgl2DTR chimera resulted in ablation of LCs (Figure S4D). These
Figure 2. Uptake of Soluble Protein Antigen
by CD301b+DDCs in the Skin-Draining LNs
Mice were injected with Alexa Fluor 488 (A488)-
labeled OVA protein with the indicated adjuvant
in the footpad. Twenty-four hr later, the draining
popliteal LNs were harvested and stained for DC
markers. The total live LN cells are shown. These
data are representative of three independent ex-
periments. See also Figure S2.
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radioresistant cells and is not a secondary effect of CD301b+
DDC removal.
CD301b+DDCs Are Required for Recruitment and
Activation of CD4+T Cells Induced by Th2-type
Adjuvants
DCs support primary immune responses by inducing LN expan-
sion and stimulating antigen (Ag)-specific T cells (Kumamoto
et al., 2011; Webster et al., 2006). To determine the role of
CD301b+ DDCs in the initiation of adaptive immune responses,
we assessed T cell priming following depletion of these cells.
Footpad injection with papain induced hypertrophy in the drain-
ing popliteal LN in WT mice (Figure 4A). In contrast, in the DT-
treated Mgl2DTR mice, dLN hypertrophy was significantly
impaired, which was largely explained by the reduction in the
number of CD4+ T, CD8+ T, and B cells, with a significant reduc-
tion in the proportion of CD4+ T cells (Figures 4B–4G). In addi-
tion, upregulation of CD69, but not CD25, in CD4+ T cells in
the dLN was abrogated in DT-treated Mgl2DTR mice (Figures
4H and 4I). The defect in CD4+ T cell accumulation and CD69
upregulation was due to the depletion of CD301b+ DDCs, but
not to the depletion of epidermal LCs, as Mgl2DTR/ WT
chimera injected with DT replete with LCs (Figure S4) also
showed the same phenotype (Figure S5). Furthermore, selective
depletion of epidermal LCs in huLangerin-DTR mice (Bobr et al.,
2010) had no effect on CD4+ T cell accumulation or CD69
expression following papain immunization (Figure S5). These
data indicate that both LN recruitment and activation of CD4+T
cells require CD301b+ DDCs, but not LCs, upon immunization
with papain.
To extend the role of CD301b+ DDCs in Th2 cell-mediated
immunity, we tested another Th2-type adjuvant, alum. Similar
to papain, immunization with alum in WT mice induced dLN
hypertrophy as well as CD69 upregulation in CD4+ T cells,
both of which were abrogated in CD301b+DDC-depleted
Mgl2DTR mice (Figures 5A–5C). In contrast, immunizationImmunity 39, 733–743,with a Th1-type adjuvant CpG induced
CD69 upregulation independently of
CD301b+ DDCs, whereas the accumula-
tion of CD4+ T cells in the dLN was still
partially impaired in CD301b+ DDC-
depleted mice (Figures 5D–5F). These
results identify CD301b+ DDCs as the
key DCs required for the optimal accu-
mulation of CD4+ T cells to the dLNs,
whereas the requirement of these cellsfor CD69 upregulation in CD4+ T cells is specific to Th2-type
adjuvants.
CD301b+ DDCs Are Required for Optimal Screening for
Antigen-Specific Naive CD4+T Cells in the dLN
To test whether CD301b+ DDCs mediate antigen-specific Th
cell priming, we adoptively transferred carboxyfluorescein suc-
cinimidyl ester (CFSE)-labeled naive OVA-specific transgenic
CD4+T cells (OT-II cells) into Mgl2DTR mice. Immunization
with OVA and papain in the footpad led to CFSE dilution in
OT-II cells in the dLN of DT-treated mice that was identical
to that of PBS-treated mice, indicating that antigen-induced
division of OT-II cells did not require CD301b+ DDCs (Fig-
ure 6A). However, reflecting the defect in accumulation of
polyclonal CD4+ T cells to the reactive dLN (Figures 4 and
5B), the absolute number of OT-II cells in the dLN was reduced
in the DT-treated mice compared to PBS-treated mice (Fig-
ure 6C). Consistently, in the nondraining LN where the circu-
lating pool is the only source of divided OT-II cells, the relative
abundance of undivided OT-II cells was larger in CD301b+
DDC-depleted mice (Figures 6A and 6D), suggesting that sys-
temically, more OT-II cells are left unscreened and thus re-
mained unprimed in the absence of CD301b+ DDCs. Together,
these results support the idea that CD301b+ DDCs are required
for the optimal screening of antigen-specific naive CD4+ T cells
within the dLN.
CD301b+ DDCs Are Required for Development of
Antigen-Specific Th2 Cells
Thus far, our data indicated that CD301b+ DDCs are required for
the maximal recruitment of naive antigen-specific CD4+ T cells
into the reaction induced by Th2-type adjuvants. To test whether
the OT-II cells primed in the absence of CD301b+ DDCs were
qualitatively affected in addition to their migration defect, we
analyzed expression of activation markers in those OT-II cells.
At 2 days after immunization with OVA and papain, OT-II cells
primed in the absence of CD301b+ DDCs had lower CD69October 17, 2013 ª2013 Elsevier Inc. 735
Figure 3. Depletion of CD301b+ DDCs in
Mgl2DTR Mice
(A) Mice of indicated genotype were intraperito-
neally injected with PBS or DT. Two days later,
skin-draining LNs were harvested and stained for
CD301b or DTR-GFP. Scale bar represents
100 mm.
(B) Skin-draining LN DCs 1 day after DT injection
were stained for CD301b and CD207+DCmarkers.
(C) Kinetics of CD301b+DDC depletion in the skin-
draining LNs in Mgl2DTR mice. The percentage of
CD301b+DCs in the total LN cells is shown as
mean ± SEM. n = 4–6 per time point.
(D) Depletion of CD301b+DDCs abolishes the
influx of hapten-bearing DCs in the dLN. DT-
treated WT C57BL/6 (WT B6) or Mgl2DTR mice
were painted with TRITC dissolved in 1:1 mixture
of acetone:di-n-butylphthalate on the shaved
abdomen. Twenty-four hr later, the draining (right)
and nondraining contralateral (left) inguinal LNs
were harvested. The total live LN cells are shown.
These data are representative of two similar ex-
periments. See also Figures S3 and S4.
Immunity
CD301b+ Dermal DCs Drive Th2 Cell Responsesexpression compared to intact mice (Figure 7A), as expected
from the CD69 defect in polyclonal CD4 T cells (Figure 4). Never-
theless, those OT-II cells that underwent division cycles upregu-
lated Th1 cell-associated activation marker CD44 (Baaten et al.,
2010; Guan et al., 2009) and transcription factor T-bet (Szabo
et al., 2000) normally (Figure 7A). By 4 days of immunization,
CD44 and T-bet expression in OT-II cells were downregulated
in cells that have undergone several divisions. However, expres-
sion of these molecules remained high upon cell division in OT-II
cells primed in CD301b+ DDC-depleted hosts (Figure 7A). In
contrast, upregulation of Th2 cell-regulator transcription factor
GATA-3 (Zhang et al., 1997; Zheng and Flavell, 1997) in divided
OT-II cells was impaired in DT-treated Mgl2DTR mice (Fig-
ure 7A), suggesting that OT-II cells primed in the absence of
CD301b+ DDC are impaired in Th2 and skewed toward Th1
phenotype.
Notably, OT-II cells primed in CD301b+ DC-depleted hosts
were severely impaired in interleukin-4 (IL-4) production (Figures
7B and 7C). The defect in IL-4 production was observed as early
as day 4 after immunization (Figure 7B), suggesting that
imprinting toward Th2 cell differentiation required CD301b+
DDCs at the very beginning of Th2 cell differentiation in vivo. In
addition, the defect in IL-4 production and the increased relative
abundance of undivided fraction of OT-II cells in the non-dLN
and spleen were also observed in mice depleted of CD301b+
DDC and immunized with OVA and alum (Figures S6A and
S6B), suggesting that the requirement of CD301b+ DDCs for
Th2 cell differentiation is not specific to papain. Interferon-g
(IFN-g) production upon infection with herpes simplex virus (Fig-
ure S6C) was generally intact or even slightly exaggerated in
CD301b+ DDC-depleted animals, indicating the selective role
of CD301b+ DDC in Th2 cell responses. Similarly, IFN-g produc-736 Immunity 39, 733–743, October 17, 2013 ª2013 Elsevier Inc.tion following immunization with CpG
was also not affected by depletion of
CD301b+ DDCs (Figure S6D). In addition,
consistent with a previous report (Tanget al., 2010), the defect in Th2 cell differentiation in Mgl2DTR
mice was not due to depletion of epidermal LCs, because
specific depletion of LCs in huLangerin-DTR mice did not result
in impaired IL-4 production (Figure S6E). Among multiple other
cellular and molecular mechanisms identified for Th2 cell-
mediated immunity to date (Paul and Zhu, 2010; Pulendran
and Artis, 2012), these results highlight the critical requirement
for CD301b+DDCs in early stages in the development of Th2
cells.
CD301b+DCs Alone Are Insufficient for the Generation
of Th2 Cell Responses
To gain mechanistic insight into the properties of CD301b+ DC
that impart upon it Th2-cell differentiation function, we next
examined surface expression of Th2 cell-associated molecules
in CD301b+DCs and other skin-derived DC subsets in the
dLNs of papain-immunized WT mice. In addition to their modest
expression of known Th2 cell-driving molecules such as ICOSL,
OX40L, and Jagged-1, CD301b+ DCs showed highest expres-
sion of receptor for IL-33, which has recently been shown to
be a potent inducer for Th2 cell differentiation and allergy (Bes-
nard et al., 2011; Rank et al., 2009) (Figure S7A). Of note,
CD301b+ DCs also expressed the highest amount of PD-L2
among other DC subsets, which is a potential regulator for Th2
cell differentiation (Ishiwata et al., 2010; Matsumoto et al.,
2008; Oflazoglu et al., 2004).
Next, we assessed the sufficiency of CD301b+ DCs in priming
Th2 cell responses in vivo. To this end, naive mice that were
given OT-II T cells were injected with CD301b+ DCs that were
sorted from papain-immunized dLNs and pulsed in vitro with
major histocompatibility complex class II (MHCII)-restricted
OVA323–339 peptide. Despite robust division of OT-II cells, we
A B C D
E F G
H I
Figure 4. Requirement of CD301b+ DDCs for Accumulation and Activation of Polyclonal CD4+T Cells in the dLN upon Immunization with
Papain
WT or Mgl2DTR mice were intraperitoneally injected with DT. One day later, the mice were immunized with papain in the right hind footpad.
(A–G) The draining right or nondraining left popliteal LNs were harvested 3 days after immunization, and the total LN cellularity (A) and the number (B–D) and the
percentage in the total dLN cells (E–G) of CD4+T cells (B and E), B cells (C and F), and CD8+T cells (D and G) are depicted.
(H and I) Expression of CD69 and CD25 was analyzed in CD4+T cells in (B) and the percentages of CD69+CD25 cells among total CD4+T cells were calculated.
Data were pooled from two independent experiments with similar results and represented as mean ± SEM. Each point represents one mouse. See also
Figure S5.
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DC transfer (Figure S7B), suggesting that additional requirement
exists to induce Th2 cell differentiation upon this mode of
immunization.
CD301b+DCs Are Required for Th2 but Not Tfh or
Germinal Center Responses Induced by N. brasiliensis
To determine the role of CD301b+ DDCs in a more physiological
setting, we infected Mgl2DTR mice with N. brasiliensis, a natural
rodent hookworm pathogen that induces strong Th2 cell re-
sponses. In this model, once injected subcutaneously, the par-
asites quickly migrate to the lung through the bloodstream,
where they expand and trigger robust type 2 cytokine produc-
tion (Camberis et al., 2003). Notably, depletion of CD301b+DDCs impaired IL-4 production from endogenous polyclonal
CD4+ T cells in the dLNs of the initial injection site (Figure 7D).
In addition, production of IL-4 by CD4+ T cells in the lung-drain-
ing mediastinal LN was also reduced, suggesting the presence
of corresponding CD301b+ DC subset in the lung that promote
Th2 cell differentiation (Figure 7D). However, CD301b+ DC-
depleted animals produced normal amount of parasite-specific
class-switched immunoglobulin G1 (IgG1) antibodies, as well as
follicular helper CD4+ T (Tfh) cells and germinal center B cells
(Figures 7E–7G). In addition, total IgE was induced comparably
in the absence of CD301b+ DC (Figure 7G). These data indicate
that upon infection with a parasite, CD301b+ DCs are required
for the development of Th2, but not Tfh or B cell responses
involving germinal center B cells, IgG1, or IgE responses.Immunity 39, 733–743, October 17, 2013 ª2013 Elsevier Inc. 737
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Figure 5. CD301b+DDC Requirement for
Activation of CD4+T Cells in Response to
Th1- and Th2-Type Adjuvants
As in Figure 4, DT-treated mice were immunized in
the right footpad with OVA and alum (A–C) or OVA
andCpG2216 (D–F). Popliteal LNswere harvested
on day 3. The total LN cellularity (A and D), the
number of CD4+T cells (B and E) and the per-
centage of CD69+CD25 cells in total CD4+T cells
(C and F) are shown. Data were pooled from two
independent experiments with similar results and
represented as mean ± SEM. Each point repre-
sents one mouse.
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In this study, we demonstrated that CD301b+ DDCs are the
major migratory DC subset that transport protein antigen upon
immunization in the footpad with papain. CD301b+DDCs were
also required for accumulation of naive CD4+T cells to the
dLNs, thereby facilitating the rate of screening for antigen-
specific T cells. Furthermore, in vivo depletion of CD301b+
DDCs resulted in loss of IL-4 production from antigen-specific
CD4+ T cells after immunization with papain or alum or after
infection with a Th2 cell-inducing parasite. Interestingly, whereas
the impaired Th1, Th2, or Th17 cell differentiation by the deple-
tion of DC subsets has been usually associated with a severe
defect in the division of antigen-specific CD4+ T cells in the
dLN (Brewig et al., 2009; Fahle´n-Yrlid et al., 2009; Hervouet
et al., 2010; Igya´rto´ et al., 2011; Kim et al., 2010; Magalhaes
et al., 2011), the depletion of CD301b+ DDCs abrogated the
differentiation of Th2 cells without affecting the division of
cognate CD4+ T cells. These data suggest that the instruction
for the Th2 cell differentiation might not be coupled to the signal
for cell division. Consistent with our study, genetic mutation that
leads to a loss of the CD301b+ DDC subset results in a similar
deficiency in Th2 cell-mediated immunity (see accompanying
study by Gao et al., 2013). Further, our results are consistent
with the previous finding that antigen coinjected with papain is
preferentially presented ex vivo by CD207 CD8a DCs (Tang
et al., 2010), which includes the CD301b+ DDC population.
Although we cannot formally rule out CD301b expression by
cell types other than DDCs, together these studies indicate the
role of CD301b+ DDC in controlling Th2 cell responses.
Compared to the notable advances over the years in under-
standing the development of other types of Th cell responses,
our understanding in the development and maintenance of Th2
cell responses is still far from complete. Although accumulating
evidence indicates involvement of DCs in Th2 cell-mediated im-
munity, either in priming or maintenance (Hammad et al., 2010;
Leo´n et al., 2012; Phythian-Adams et al., 2010; Smith et al.,
2011; Tang et al., 2010), the key DC subset required for Th2
cell-mediated immunity in vivo, particularly in the skin, has not738 Immunity 39, 733–743, October 17, 2013 ª2013 Elsevier Inc.been well characterized. In the lung, a
recent work by Lambrecht and col-
leagues demonstrates that CD11b+ DCs
and FcεRI+ monocyte-derived DCs are
required for infiltration of eosinophilsand other cell types in the lung, a hallmark of type 2 inflammation
induced by inhalation of house dust mite extracts (Hammad
et al., 2010; Plantinga et al., 2013). However, given that eosino-
philic infiltration and type 2 cytokine production do not neces-
sarily require CD4+ T cells (Halim et al., 2012), it remains to be
determined whether a specific subset of DCs is required for
Th2 cell differentiation. Our current study shows that in the
skin, the CD301b+ DDC subset plays a key role in the generation
of Th2 immunity after allergen and helminth challenge.
It was reported previously that a subset of DCs in certain con-
ditions is sufficient to promote Th2 cell differentiation when
loaded with antigen and injected into naive recipients (Hammad
et al., 2010; Maldonado-Lo´pez et al., 1999; Pulendran et al.,
1999; Smith et al., 2012). Similarly, sensitization with CD301b+
DCs alone is sufficient for developing contact hypersensitivity
against FITC, a typical Th2 cell-type hapten (Kumamoto et al.,
2009). In contrast, other studies have shown an additional
requirement of non-DC accessory cells such as basophils in
Th2 cell differentiation in somemodels including papain-induced
skin immunity (Otsuka et al., 2013; Perrigoue et al., 2009; Sokol
et al., 2009; Tang et al., 2010). Our results are consistent with the
latter, in that adoptive transfer of CD301b+ DCs isolated from LN
draining papain injection site is not sufficient to prime Th2 cell-
mediated immune responses in the recipient host. Thus, the
other cell types involved in orchestrating Th2 priming in vivo re-
mains to be elucidated.
With regards to antibody responses, our results with
N. brasiliensis infection indicated no impairment in the germinal
center B cells, IgG1, or IgE responses in mice depleted of
CD301b+ DCs. Further, our results suggest that development
of T follicular helper (Tfh) cells can be uncoupled and might
require a distinct DC subset from development of Th2 cell re-
sponses. Although function of Th2 and Tfh cells has often been
considered interchangeable for type 2 inflammation, the fact
that Tfh cell-defective Bcl6-deficient animals show an enhanced
Th2 cell response (Dent et al., 1997) and that an instructive signal
from APC is required for Bcl6 expression in Tfh cell development
(Choi et al., 2011) strongly support the idea that those two types
of CD4+ T cells require different APCs for their differentiation.
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Figure 6. Requirement of CD301b+DDCs for the Optimal Screening for Antigen-Specific CD4+ T Cells upon Immunization with Papain
Mgl2DTR mice were adoptively transferred with CFSE-labeled OVA-specific naive OT-II CD4+ T cells, and treated with DT or PBS. One day later, the mice were
immunized with OVA and papain in the footpad. The draining and nondraining LNs were harvested 4 days after immunization.
(A) Dilution of CFSE in OT-II cells.
(B) The number of endogenous polyclonal CD4+T cells per LN.
(C) The number of OT-II cells per LN.
(D) The percentage of undivided CFSEhi cells among OT-II cells. Data were pooled from two independent experiments with similar results and represented as
mean ± SEM. Each point represents one mouse.
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phils or total CD11c+ DC population abrogates Th2 cell
responses (Hammad et al., 2010; Otsuka et al., 2013; Phy-
thian-Adams et al., 2010; Smith et al., 2012; Sokol et al.,
2008; Tang et al., 2010). The relatively narrow time window of
the basophil presence in the dLN restricts their interaction
with only a limited subset of migratory DCs, a time course
consistent with CD301b+ DDC migration. In addition, the accu-
mulation of CD4+ T cells mediated by CD301b+ DDC might
facilitate interaction of CD4+ T cells with late-arising Th2 cell
drivers such as late-activator APCs (Yoo et al., 2010) or che-
mokine receptor CXCR5-expressing conventional DCs (Leo´n
et al., 2012). The unique ability of CD301b+ DDC to promote
Th2 cell responses likely involves mechanisms at different
levels. First, as shown in this study, CD301b+ DDCs express
several Th2 cell-associated molecules including IL-33 receptor
(this study), as well as very high amount of CD40 even at the
steady state (Kumamoto et al., 2009), a molecule required for
Th2 cell-mediated immunity (MacDonald et al., 2002). Second,
CD301b+ DDCs are the major antigen-bearing DCs in the dLN
early after immunization with papain. Third, CD301b+ DDCs
provide signals in the LN needed to both increase the size of
naive precursor pool and to retain antigen-specific CD4+T cells
for optimal Th2 cell differentiation. CD69 acts as a LN retention
signal for antigen-specific lymphocytes by inhibiting sphingo-
sine-1-phosphate receptor 1 downstream of type I IFN recep-
tor (Shiow et al., 2006). Although CpG is a well-known inducer
of type I IFN, the absolute requirement of CD301b+ DDC for
CD69 upregulation by CD4+ T cells upon immunization with
papain or alum suggests an intriguing possibility that DDCs
replace the role of type I IFNs during helminth infection for
retention of pathogen-specific CD4+ T cells. In addition to
demonstrating the requirement for DDCs, the results of our
studies have implications for treatment of Th2 cell-mediated
diseases. Modulating the function of CD301b+ DDCs might
be a potential therapeutic target for atopic dermatitis and other
type of allergic diseases in which Th2 cells are implicated
(Cookson, 2004).EXPERIMENTAL PROCEDURES
Mice
Age- and sex-matched 2- to 5-month-old mice were used in each experi-
mental group. C57BL/6 (B6) and B6.SJL-PtprcaPep3b/BoyJ (congenic
CD45.1mice onB6 background) were obtained fromNational Cancer Institute.
For generating Mgl2DTR mice, a DTR-GFP cassette (gift from Steffen Jung)
linked to a floxed neomycin-resistant cassette (NeoR) was targeted into
Mgl2 exon 2 in bacterial artificial chromosome (BAC) R23-67I17 by recombina-
tion-mediated genetic engineering (gift from Neal Copeland). The recombined
allele was then retrieved onto a targeting vector pEZ-Frt-lox-DT (Schenten
et al., 2002) (gift fromDominik Schenten) and linearized by digestingwith SacII.
The linearized vector was electroporated into B6 embryonic stem cells (ESCs).
Successfully-recombined ESC clone was identified by Southern blotting and
injected into WT B6 mice. The probes used for Southern blotting were ampli-
fied from BAC R23-67I17 by using specific primers (probe 1 forward primer:
agaggaatatgggacggcacact, probe 1 reverse primer: aggccacaacccaagcta
gagtgc, probe 2 forward primer: atcttgccaggctggtcattgttaagttca, probe 2
reverse primer: gtatcatggatgtagcctccctgtcatttatag) and labeled with Redi-
prime II (GE Healthcare). The offspring were tested for the presence of DTR-
GFP cassette by PCR (forward primer: agcaaagaccccaacgagaa, reverse
primer: cgtccatgccgagagtgat) in the genomic DNA and backcrossed once
with B6.FVB-Tg(EIIa-Cre) mice (gift from Richard Flavell) to remove the floxed
NeoR. The NeoR-removed Mgl2DTR mice were maintained on WT B6 back-
ground. The removal of NeoR and EIIa-cre transgene from the genomic DNA
was confirmed by PCR (NeoR forward primer: tgatcgacaagaccggcttcca,
NeoR reverse primer: tgcatacgcttgatccggctac, Cre forward primer:
gcggtctggcagtaaaaactatc, Cre reverse primer: gtgaaacagcattgctgtcactt). In
the case we needed to distinguishMgl2DTR/DTR homozygotes from the hetero-
zygotic Mgl2DTR mice, the WT Mgl2 exon 2 was detected by PCR (forward
primer: tgcgtttgtcaaaacatgacaatgagatat, reverse primer: atacttagagcaaac
tttggagactccat). CD45.1 OT-II TCR transgenic mice (gift from Richard Flavell)
were maintained on Rag1/ background. HuLang-DTR transgenic mice were
a gift from Daniel Kaplan. For bone-marrow chimera experiments, mice were
irradiated with two doses of 475 rads and transplanted with 106 bone-
marrow cells. All bone-marrow chimeric mice were treated with Sulfatrim in
drinking water for 4 weeks and then maintained on regular water for another
4 or more weeks before being used in experiments. All procedures used in
this study complied with federal guidelines and institutional policies of the
Yale Animal Care and Use Committee.
Immunization
All immunization procedures were conducted in the rear footpad with 20 ml




Figure 7. Requirement of CD301b+DDCs for
the Papain- and Hookworm-Induced Th2
Cell Differentiation
(A–C) Mgl2DTR mice were adoptively transferred
with CFSE-labeled OT-II cells and treated with DT
or PBS as in Figure 6. (A) The OT-II cells were
subdivided based on the number of divisions as
shown in Figure 6A. Mean fluorescent intensity of
indicated markers in OT-II cells are depicted
against the number of cell divisions. The data are
representative of two independent experiments
and shown as mean ± SEM n = 3 for each time-
point. (B and C) The draining popliteal LNs and
spleen were harvested on day 4 (B) or day 8 (B and
C) after immunization and restimulated in vitro with
PMA and ionomycin for intracellular cytokine
staining in gated OT-II cells.
(D–G) Mgl2DTR mice were treated with either PBS
or DT every 3 days starting at day 1. On day
0, mice were subcutaneously infected with
N.brasiliensisat the tail base.Atday5 (D)andday13
(E and F), indicated LNswere collected and stained
for IL-4 following restimualtion with PMA and ion-
omycin (D) or for Tfh cell markers PD-1 and CXCR5
and germinal center B cell markers CD95 and GL7
without restimulation (E andF). Percentages among
total CD4+ T (D and E) and B (F) cells are shown.
Sera were harvested before infection (day 0) or on
day13andparasite-specificantibodywasdetected
by ELISA (G). Data were pooled from two indepen-
dent experiments with similar results and repre-
sentedasmean±SEM.SeealsoFiguresS6andS7.
Immunity
CD301b+ Dermal DCs Drive Th2 Cell ResponsesDT (List Biological Laboratories) was injected intraperitoneally. For in vivo an-
tigen-uptake experiments, WT B6 mice were injected in both hind legs with
2 mg Alexa Fluor 488-conjugated OVA together with 50 mg papain (Sigma) or
CpG2216 (Invivogen). The draining popliteal LNs were harvested for analysis
24 hr after immunization. For LN T cell accumulation and activation, WT B6,
Mgl2DTR, or huLang-DTR mice were treated with DT on days 1 and +1.
On day 0, they were immunized with 50 mg papain (without OVA), 10 mg
CpG2216 with 5 mg purified OVA (Worthington Biochemical Corporation), or740 Immunity 39, 733–743, October 17, 2013 ª2013 Elsevier Inc.5 mg OVA precipitated in 50% alum in PBS (Imject
Alum, Thermo Scientific) in the right hind leg. On
day 3, the left nondraining and the right draining
popliteal LNs were harvested for analysis. For
OT-II transfer experiments, CD4+T cells were iso-
lated from naive CD45.1Rag1/OT-II animals by
MACS cell sorter with mouse CD4+T cell isolation
kit (Miltenyi Biotec) and labeled with CFSE
(Invitrogen) according to the manufacturer’s proto-
col. One million OT-II cells were adoptively trans-
ferred retro-orbitally into Mgl2DTR recipients on
day 1 that were subsequently treated with DT
or PBS 2 hr after the adoptive transfer. The
depleted or undepleted recipients were then
immunized on day 0 with 5 mg purified OVA with
50 mg papain in the both hind legs and treated
with DT or PBS every 2–3 days. The draining popli-
teal LNs (on both sides), nondraining brachial LNs,
and the spleen were harvested on days 4 and 8.
For adoptive immunization with sorted DC sub-
sets, WT donor mice were subcutaneously immu-
nized with papain in the footpads and in the tail
base, and then DCs were isolated with MACS cell
sorter by using anti-CD11c Microbeads (Miltenyi
Biotec) from axillary, brachial, inguinal, and popli-teal dLNs 24 hr after immunization. Isolated DCs were then stained for
CD11c, MHCII, and CD301b, and CD301b+ or CD301b MHCIIhi DCs were
sorted by FACSAria II cell sorter (>95% purity). The sorted DCs were pulsed
with 10 mg/ml OVA323–339 peptide for 60 min, washed extensively with PBS,
and injected into the right footpad of naive WT mice that had been given naive
OT-II cells one day earlier. Seven days after adoptive immunization, the drain-
ing popliteal LNs were harvested and stimulated with PMA and ionomycin for
further analysis.
Immunity
CD301b+ Dermal DCs Drive Th2 Cell ResponsesN. brasiliensis Infection and Detection of Serum Antibodies
Mice were treated with DT every third day starting on day 1. On day 0, mice
were injected subcutaneously at the tail base with 500 worms per mouse third-
stage larvae (L3) of N. brasiliensis in 0.2 ml PBS with gentamycin (GIBCO). For
serum antibody ELISA against L3 antigens, the L3 larvae were sonicated and
homogenized and used as coating antigens for ELISA. For detecting anti-L5
serum antibodies, stage 5 (L5) were isolated from intestines of mice infected
with L3 larvae 7 days earlier and homogenated. Five micrograms of lysates
were used to coat microtiter plates, which were then incubated with the
sera, then with anti-mouse IgG1 and IgE secondary antibodies (Southern
Biotech).
Flow Cytometry
For staining surface antigens, LNs and spleens wereminced and digested with
2 mg/ml collagenase D (Roche) for 30 min. In the case of splenocytes, eryth-
rocytes were lysed by briefly suspending cells in ACK lysis buffer. Cells were
resuspended in 2 mM EDTA in PBS and incubated with fluorochrome-conju-
gated mAb cocktail for 20 min on ice. For intranuclear transcriptional-factor
staining, cells were fixed and permeabilized with Foxp3 Fixation/Permeabiliza-
tion Concentrate and Diluent (eBioscience). For intracellular cytokine staining,
cells were stimulated in a 96-well round-bottom plate with 20 ng/ml PMA and
1 mg/ml ionomycin (Sigma) for 1.5 hr at 37C, then incubated another 4.5 hr at
37C with additional Protein Transport Inhibitor Cocktail (eBioscience). Cells
were then fixed and permeabilized with BD Cytofix/Cytoperm Kit (BD Biosci-
ences), then incubated with anti-cytokine mAbs for 60 min on ice. Anti-CD4
(GK1.5), CD8a (53-6.7), CD25 (PC61), CD11b (M1/70), CD11c (N418), CD45
(30-F11), CD45.1 (A20), CD45.2 (104), CD326 (G8.8), OX40L (RM134L),
IFN-g (XMG1.2), and IL-4 (11B11) mAbs were purchased from BioLegend.
Anti-CD44 (IM-7), CD103 (2E7), T-bet (4B10), Jagged-1 (HMJ1-29), PD-L2
(TY25), ICOSL (HK5.3), and GATA-3 (TWAJ) mAbs were purchased from
eBioscience. Anti-B220 (RA3-6B2), CXCR5 (2G8), CD95 (Jo2), and GL7
mAbs were purchased from BD Biosciences. Anti-pan CD301 mAb (ER-
MP23) was purchased from Santa Cruz Biotechnology. Anti-IL-33 receptor
(245707) was purchased from R&D systems. Anti-MHCII (M5/114.15.2) mAb
was purified in house from the culture supernatant of the hybridoma and con-
jugated with Alexa Fluor 680 (Invitrogen). All flow-cytometry samples were
scanned on BD FACS LSRII (BD Biosciences) and analyzed by FlowJo soft-
ware (Version 9.3.2, TreeStar).
Anti-CD301b Hybridoma
Anti-CD301b hybridoma 11A10-B7-2 was established by standard limiting
dilution of YB2/0 rat myeloma cells fused with dLN cells of rats immunized re-
combinant CD301b. Complementary DNA clones forMgl1 andMgl2were pur-
chased fromOpenBiosystems (clone ID 4456238 and 40044847, respectively),
and the extracellular domain of each protein was amplified by PCR (common
forward primer: catgccatgggatcccaaaattcccagttaa, Mgl1 reverse primer:
ccgctcgagtaaattacttggcgagagct, Mgl2 reverse primer: ccgctcgagttatggaact-
gaggctataa) and cloned into NcoI and XhoI sites of pET21d vector (gift from
Ruslan Medzhitov). The recombinant proteins were expressed in Rosetta
(DE3) E. coli (Novagen) and purified with a lactose-agarose column (Sigma)
as previously described (Kumamoto et al., 2004). To immunize, two female
WKY rats were injected in the footpad on both hind legs with 0.1 mg recombi-
nant CD301b together with TiterMaxGold (CytRx) on days 0, 5, and 13. On day
14, the draining popliteal and inguinal LNs were excised and pooled, and then
the cells were fusedwith YB2/0 nonsecreting rat myeloma cells and selected in
a standard HAT media. One CD301b-specific clone, 11A10-B7-2 (IgG2a, l),
that does not cross-react with CD301a was selected by ELISA of the superna-
tant against recombinant CD301a and CD301b proteins and subcloned by
limiting dilution. The hybridoma cells were cultured in serum-free media (CD
hybridoma, Invitrogen) supplemented with 0.53 cholesterol (Invitrogen) and
insulin-transferrin-selenium supplement (Sigma), and the mAb was purified
from the culture supernatant with protein G-agarose (Millipore). For the use
in flow-cytometry, purified 11A10-B7-2 mAb was labeled with Lightning-Link
APC Antibody Labeling Kit (Novus Biologicals).
Immunohistochemistry
Axillary and brachial LNs were removed from DT- or PBS-treated WT B6 or
Mgl2DTR mice and frozen in OCT compound (Sakura Finetek). Frozen sec-tions (8 mm thickness) were fixed in ice-cold acetone and nonspecific binding
was blocked by preincubating the sections with 5% bovine serum albumin,
1% normal goat serum in PBS. The sections were incubated with 2.5 mg/ml
purified anti-CD301b 11A10-B7 mAb or rabbit anti-GFP polyclonal Ab
(Invitrogen). Biotinylated donkey anti-rat IgG (H+L) and donkey anti-rabbit
IgG (H+L) (Jackson ImmunoResearch) were used to detect mAb CD301b
and anti-GFP polyclonal Ab, respectively. After incubating with the secondary
Abs, the bound Abs were detected by streptavidin-horseradish peroxidase
(Zymed) and Tyramide-Cy3 (PerkinElmer). For double staining, fixed sections
were first incubated with anti-CD207 (929F3) or anti-CD11c (N418) mAbs, fol-
lowed by secondary antibodies biotinylated donkey anti-rat IgG (H+L) and
donkey anti-hamster IgG (H+L) (Jackson ImmunoResearch), respectively.
The secondary Abs were detected by SA-HRP and Tyramide-Cy3. The sec-
tions were then incubated with biotin-conjugated anti-mouse MGL2 (R&D)
that was subsequently detected by SA-HRP and Tyramide-FITC. The nuclei
were stained with DAPI. Images were captured by BX51 fluorescence micro-
scope (Olympus) and processed with PictureFrame software (Optronics).
Statistical Analysis
All experiments were performed at least twice and the data were pooled where
indicated. All p values were calculated by two-tailed Student’s t test by Prism
software (version 4.0b, GraphPad). Data are presented as mean ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.immuni.2013.08.029.
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